Novartis to pay $3.1B for Cambridge biotech led by former Karuna CEO
In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now locked in another big biotech deal.
Amphista Therapeutics appoints Paul Medeiros as Chief Business Officer
Amphista Therapeutics appoints Paul Medeiros as Chief Business OfficerAppointment supports the Company’s ambitions to advance its portfolio of ...
Meet the Cambridge researchers exploring psychedelic-assisted therapies
Ruby Jackson speaks to the psychiatrist researching the therapeutic potential of psychedelics ...
TheStreet.com4y
IPO Launch: Sigilon Therapeutics Proposes Terms For $101 Million IPO
Cambridge, Massachusetts-based Sigilon was founded to develop its Shielded Living Therapeutics platform ... Also, the availability of limited treatment therapies is encouraging further R&D efforts ...
Optimistic Outlook for Tectonic Therapeutic’s TX45: A Promising Candidate for Unmet Medical Needs
Analyst David Risinger from Leerink Partners reiterated a Buy rating on Tectonic Therapeutic (TECX – Research Report) and increased the price ...
Nature2y
Microbiotica—unlocking the microbiome as a multi-therapeutic modality
Microbiotica was founded in 2016 in Cambridge, UK, to translate pioneering ... bacterial signatures to design microbiome-based therapeutics and biomarkers (Fig. 1). Using this clinic-first ...